Pregnancy Autoantibody Blocks Fetal Liver Glycogen via PI3K/AKT Suppression
AT1-AA, found in up to 50% of preeclampsia patients, uniquely impairs fetal hepatic glycogen storage by inhibiting a key insulin-signaling pathway.
Summary
Researchers at Capital Medical University discovered that AT1-AA, an autoantibody present in up to half of preeclampsia patients, specifically reduces hepatic glycogen in fetal rat livers during late gestation. Unlike angiotensin II or L-NAME—which cause similar placental ischemia and growth restriction—AT1-AA uniquely suppresses glycogen synthesis by inhibiting the PI3K/AKT signaling pathway via AT1R activation. This reduces expression and activity of GYS2, the liver's primary glycogen-synthesizing enzyme. Blocking AT1R with telmisartan or valsartan, or directly activating PI3K/AKT, restored normal glycogen synthesis. The findings identify AT1-AA as a distinct maternal risk factor for fetal metabolic programming with potential implications for neonatal hypoglycemia prevention.
Detailed Summary
Fetal hepatic glycogen is a critical energy reserve supporting intrauterine development and postnatal metabolic adaptation. Insufficient glycogen stores are linked to neonatal hypoglycemia, neurodevelopmental impairments, and increased adult risk of type 2 diabetes, non-alcoholic fatty liver disease, and glucose intolerance. Identifying specific maternal factors that disrupt fetal glycogen homeostasis is therefore a priority for perinatal medicine.
This study investigated the role of angiotensin II type 1 receptor autoantibody (AT1-AA), an agonistic IgG autoantibody detected in ~50% of preeclampsia patients, in disrupting fetal hepatic glycogen during late pregnancy. AT1-AA-positive pregnant rat models were established by intravenous administration of purified AT1-AA on gestational days 13 and 15. Control groups included saline, AT1-AA-negative IgG, angiotensin II (Ang II), and L-NAME, enabling researchers to distinguish AT1-AA-specific effects from nonspecific IgG elevation, vasoconstriction, or general AT1R agonism.
Key findings revealed that AT1-AA uniquely reduced fetal hepatic glycogen content at gestational day 18, as confirmed by PAS staining and anthrone-sulfuric acid assay. Strikingly, neither L-NAME nor Ang II—despite inducing similar placental ischemia and fetal growth restriction—reduced glycogen. In fact, Ang II increased fetal hepatic glycogen, highlighting the mechanistic specificity of AT1-AA. The glycogen reduction was traced to impaired synthesis rather than accelerated breakdown: GYS2 protein expression and glycogen synthase (GS) enzymatic activity were significantly reduced in the AT1-AA group, while PYGL expression and glycogen phosphorylase (GP) activity were largely unaffected.
RNA sequencing of fetal livers from AT1-AA-exposed versus saline-exposed rats identified suppression of the PI3K/AKT signaling pathway as the dominant transcriptomic alteration. Western blot analyses in fetal liver tissue and in HepG2 human hepatoma cells confirmed reduced PI3K and phospho-AKT levels following AT1-AA treatment. Crucially, this suppression was AT1R-dependent: genetic knockdown of AT1R via siRNA, or pharmacological blockade with telmisartan or valsartan, reversed PI3K/AKT inhibition and restored GYS2 expression and GS activity. Direct activation of PI3K/AKT with the agonist 740Y-P similarly rescued glycogen synthesis, confirming the pathway's causal role.
These results establish AT1-AA as a distinct maternal pathogenic factor that crosses the placental barrier and directly programs fetal hepatic metabolism by suppressing a key insulin-signaling node. The mechanistic divergence from Ang II—despite both acting on AT1R—suggests AT1-AA engages receptor conformations or downstream biases that differ from canonical angiotensin signaling. Clinically, this raises the possibility that AT1R blockade or PI3K/AKT pathway support during AT1-AA-positive pregnancies could mitigate fetal metabolic risk.
Key Findings
- AT1-AA uniquely reduced fetal hepatic glycogen at gestational day 18; Ang II and L-NAME did not despite similar growth restriction.
- AT1-AA impaired glycogen synthesis by decreasing GYS2 expression and glycogen synthase activity, not by increasing glycogen breakdown.
- RNA sequencing identified PI3K/AKT pathway suppression as the predominant mechanism underlying AT1-AA-induced glycogen reduction.
- AT1R blockade (telmisartan, valsartan, siRNA) or PI3K/AKT activation (740Y-P) fully rescued glycogen synthesis in vitro.
- AT1-AA effects were independent of nonspecific IgG elevation, confirmed by an AT1-AA-negative IgG control group.
Methodology
AT1-AA-positive pregnant rat models (n=6/group, 5 groups) received purified AT1-AA intravenously on gestational days 13 and 15; controls included saline, IgG-negative, Ang II, and L-NAME groups. Fetal livers were assessed via PAS staining, anthrone-sulfuric acid glycogen assay, RNA sequencing (BGISEQ), and Western blot on gestational day 18. In vitro validation used HepG2 hepatoma cells with siRNA knockdown, pharmacological AT1R blockers, and PI3K/AKT activator.
Study Limitations
The study relied on a rat model and HepG2 cell line, limiting direct translation to human pregnancy physiology. Only gestational day 18 was assessed for glycogen endpoints, leaving longitudinal dynamics and postnatal outcomes unexplored. The mechanistic divergence between AT1-AA and Ang II at AT1R—despite both activating the receptor—warrants further structural and signaling characterization.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: